PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurotherwww.springer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
Neurotherapeutics. 2010 January; 7(1): 31–42.
PMCID: PMC2842949
NIHMSID: NIHMS169843

Calpain as a therapeutic target in traumatic brain injury

Summary

The family of calcium-activated neutral proteases, calpains, appears to play a key role in neuropathologic events following traumatic brain injury (TBI). Neuronal calpain activation has been observed within minutes to hours after either contusive or diffuse brain trauma in animals, suggesting that calpains are an early mediator of neuronal damage. Whereas transient calpain activation triggers numerous cell signaling and remodeling events involved in normal physiological processes, the sustained calpain activation produced by trauma is associated with neuron death and axonal degeneration in multiple models of TBI. Nonetheless, the causal relationship between calpain activation and neuronal death is not fully understood. Much remains to be learned regarding the endogenous regulatory mechanisms for controlling calpain activity, the roles of different calpain isoforms, and the in vivo substrates affected by calpain. Detection of stable proteolytic fragments of the submembrane cytoskeletal protein αII-spectrin specific for cleavage by calpains has been the most widely used marker of calpain activation in models of TBI. More recently, these protein fragments have been detected in the cerebrospinal fluid after TBI, driving interest in their potential utility as TBI-associated biomarkers. Post-traumatic inhibition of calpains, either direct or indirect through targets related to intracellular calcium regulation, is associated with attenuation of functional and behavioral deficits, axonal pathology, and cell death in animal models of TBI. This review focuses on the current state of knowledge of the role of calpains in TBI-induced neuropathology and effectiveness of calpain as a therapeutic target in the acute post-traumatic period.

Key Words: Biomarker, calcium, neuroprotection, protease, proteolysis, spectrin

References

1. Bevers MB, Neumar RW. Mechanistic role of calpains in postischemic neurodegeneration. J Cereb Blood Flow Metab. 2008;28:655–673. doi: 10.1038/sj.jcbfm.9600595. [PubMed] [Cross Ref]
2. Hosfield CM, Elce JS, Davies PL, Jia Z. Crystal structure of calpain reveals the structural basis for Ca2+-dependent protease activity and a novel mode of enzyme activation. EMBO J. 1999;18:6880–6889. doi: 10.1093/emboj/18.24.6880. [PubMed] [Cross Ref]
3. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83:731–801. [PubMed]
4. Wu HY, Lynch DR. Calpain and synaptic function. Mol Neurobiol. 2006;33:215–236. doi: 10.1385/MN:33:3:215. [PubMed] [Cross Ref]
5. Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol. 2008;38:78–100. doi: 10.1007/s12035-008-8036-x. [PMC free article] [PubMed] [Cross Ref]
6. Kampfl A, Posmantur R, Nixon R, et al. mu-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J Neurochem. 1996;67:1575–1583. doi: 10.1046/j.1471-4159.1996.67041575.x. [PubMed] [Cross Ref]
7. Saatman KE, Bozyczko-Coyne D, Marcy V, Siman R, McIntosh TK. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol. 1996;55:850–860. doi: 10.1097/00005072-199607000-00010. [PubMed] [Cross Ref]
8. Arai A, Vanderklish P, Kessler M, Lee K, Lynch G. A brief period of hypoxia causes proteolysis of cytoskeletal proteins in hippocampal slices. Brain Res. 1991;555:276–280. doi: 10.1016/0006-8993(91)90352-V. [PubMed] [Cross Ref]
9. Hiramatsu K, Kassell NF, Lee KS. Improved posthypoxic recovery of synaptic transmission in gerbil neocortical slices treated with a calpain inhibitor. Stroke. 1993;24:1725–1728. [PubMed]
10. Ray SK, Hogan EL, Banik NL. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Brain Res Rev. 2003;42:169–185. doi: 10.1016/S0165-0173(03)00152-8. [PubMed] [Cross Ref]
11. Zhao X, Posmantur R, Kampfl A, et al. Subcellular localization and duration of mu-calpain and m-calpain activity after traumatic brain injury in the rat: a casein zymography study. J Cereb Blood Flow Metab. 1998;18:161–167. doi: 10.1097/00004647-199802000-00006. [PubMed] [Cross Ref]
12. Saatman KE, Abai B, Grosvenor A, Vorwerk CK, Smith DH, Meaney DF. Traumatic axonal injury results in biphasic calpain activation and retrograde transport impairment in mice. J Cereb Blood Flow Metab. 2003;23:34–42. doi: 10.1097/00004647-200301000-00004. [PubMed] [Cross Ref]
13. Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma. 2005;22:252–265. doi: 10.1089/neu.2005.22.252. [PubMed] [Cross Ref]
14. Kupina NC, Nath R, Bemath EE, et al. The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma. 2001;18:1229–1240. doi: 10.1089/089771501317095269. [PubMed] [Cross Ref]
15. Biiki A, Siman R, Trojanowski JQ, Povlishock JT. The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. J Neuropathol Exp Neurol. 1999;58:365–375. doi: 10.1097/00005072-199904000-00007. [PubMed] [Cross Ref]
16. McGinn MJ, Kelley BJ, Akinyi L, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. J Neuropathol Exp Neurol. 2009;68:241–249. doi: 10.1097/NEN.0b013e3181996bfe. [PMC free article] [PubMed] [Cross Ref]
17. Huh JW, Franklin MA, Widing AG, Raghupathi R. Regionally distinct patterns of calpain activation and traumatic axonal injury following contusive brain injury in immature rats. Dev Neurosci. 2006;28:466–476. doi: 10.1159/000094172. [PubMed] [Cross Ref]
18. Kupina NC, Detloff MR, Bobrowski WF, Snyder BJ, Hall ED. Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury. Exp Neurol. 2003;180:55–73. doi: 10.1016/S0014-4886(02)00048-1. [PubMed] [Cross Ref]
19. Pike BR, Zhao X, Newcomb JK, et al. Regional calpain and caspase-3 proteolysis of α-spectrin after traumatic brain injury. Neuroreport. 1998;9:2437–2442. doi: 10.1097/00001756-199808030-00002. [PubMed] [Cross Ref]
20. Deng Y, Thompson BM, Gao X, Hall ED. Temporal relationship of peroxynitrite-induced oxidative damage, calpain-mediated cytoskeletal degradation and neurodegeneration after traumatic brain injury. Exp Neurol. 2007;205:154–165. doi: 10.1016/j.expneurol.2007.01.023. [PMC free article] [PubMed] [Cross Ref]
21. Thompson SN, Gibson TR, Thompson BM, Deng Y, Hall ED. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice. Exp Neurol. 2006;201:253–265. doi: 10.1016/j.expneurol.2006.04.013. [PubMed] [Cross Ref]
22. DeRidder MN, Simon MJ, Siman R, Auberson YP, Raghupathi R, Meaney DF. Traumatic mechanical injury to the hippocampus in vitro causes regional caspase-3 and calpain activation that is influenced by NMDA receptor subunit composition. Neurobiol Dis. 2006;22:165–176. doi: 10.1016/j.nbd.2005.10.011. [PubMed] [Cross Ref]
23. Pike BR, Zhao X, Newcomb JK, Glenn CC, Anderson DK, Hayes RL. Stretch injury causes calpain and caspase-3 activation and necrotic and apoptotic cell death in septo-hippocampal cell cultures. J Neurotrauma. 2000;17:283–298. doi: 10.1089/neu.2000.17.283. [PubMed] [Cross Ref]
24. McCracken E, Hunter AJ, Patel S, Graham DI, Dewar D. Calpain activation and cytoskeletal protein breakdown in the corpus callosum of head-injured patients. J Neurotrauma. 1999;16:749–761. doi: 10.1089/neu.1999.16.749. [PubMed] [Cross Ref]
25. Newcomb JK, Kampfl A, Posmantur RM, et al. Immunohistochemical study of calpain-mediated breakdown products to a-spectrin following controlled cortical impact injury in the rat. J Neurotrauma. 1997;14:369–383. doi: 10.1089/neu.1997.14.369. [PubMed] [Cross Ref]
26. Huh JW, Widing AG, Raghupathi R. Basic science; repetitive mild non-contusive brain trauma in immature rats exacerbates traumatic axonal injury and axonal calpain activation: a preliminary report. J Neurotrauma. 2007;24:15–27. doi: 10.1089/neu.2006.0072. [PubMed] [Cross Ref]
27. Maki M, Takano E, Mori H, et al. All four internally repetitive domains of pig calpastatin possess inhibitory activities against calpains I and II. FEBS Lett. 1987;223:174–180. doi: 10.1016/0014-5793(87)80531-8. [PubMed] [Cross Ref]
28. Hood JL, Logan BB, Sinai AP, Brooks WH, Roszman TL. Association of the calpain/calpastatin network with subcellular organelles. Biochem Biophys Res Commun. 2003;310:1200–1212. doi: 10.1016/j.bbrc.2003.09.142. [PubMed] [Cross Ref]
29. Garcia M, Bondada V, Geddes JW. Mitochondrial localization of mu-calpain. Biochem Biophys Res Commun. 2005;338:1241–1247. doi: 10.1016/j.bbrc.2005.10.081. [PubMed] [Cross Ref]
30. Tremper-Wells B, Vallano ML. Nuclear calpain regulates Ca2+-dependent signaling via proteolysis of nuclear Ca2+/calmodulin-dependent protein kinase type IV in cultured neurons. J Biol Chem. 2005;280:2165–2175. doi: 10.1074/jbc.M410591200. [PubMed] [Cross Ref]
31. Kilinc D, Gallo G, Barbee KA. Mechanical membrane injury induces axonal beading through localized activation of calpain. Exp Neurol. 2009;219:553–561. doi: 10.1016/j.expneurol.2009.07.014. [PMC free article] [PubMed] [Cross Ref]
32. Tullio RD, Passalacqua M, Avema M, Salamino F, Melloni E, Pontremoli S. Changes in intracellular localization of calpastatin during calpain activation. Biochem J. 1999;343:467–472. doi: 10.1042/0264-6021:3430467. [PubMed] [Cross Ref]
33. Newcomb JK, Pike BR, Zhao X, Banik NL, Hayes RL. Altered calpastatin protein levels following traumatic brain injury in rat. J Neurotrauma. 1999;16:1–11. doi: 10.1089/neu.1999.16.1. [PubMed] [Cross Ref]
34. De Tullio R, Avema M, Stifanese R, et al. Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons. Arch Biochem Biophys. 2007;465:148–156. doi: 10.1016/j.abb.2007.05.007. [PubMed] [Cross Ref]
35. Foozer H, Surles N, Kizhakke Madathil S, Saatman K. Behavioral dysfunction and histological damage in calpastatin knockout mice after controlled cortical impact injury. J Neurotrauma. 2007;24:1250–1250.
36. Ringger NC, Tolentino PJ, McKinsey DM, Pike BR, Wang KK, Hayes RL. Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats. J Neurotrauma. 2004;21:829–841. doi: 10.1089/0897715041526177. [PubMed] [Cross Ref]
37. Guttmann RP, Elce JS, Bell PD, Isbell JC, Johnson GV. Oxidation inhibits substrate proteolysis by calpain I but not autolysis. J Biol Chem. 1997;272:2005–2012. doi: 10.1074/jbc.272.3.2005. [PubMed] [Cross Ref]
38. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics. 2010;7:51–61. doi: 10.1016/j.nurt.2009.10.021. [PMC free article] [PubMed] [Cross Ref]
39. Roberts-Lewis JM, Savage MJ, Marcy VR, Pinsker LR, Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci. 1994;14:3934–3944. [PubMed]
40. Saido TC, Yokota M, Nagao S, et al. Spatial resolution of fodrin proteolysis in postischemic brain. J Biol Chem. 1993;268:25239–25243. [PubMed]
41. Wang KK. Calpain and caspase: can you tell the difference? Trends Neurosci. 2000;23:20–26. doi: 10.1016/S0166-2236(99)01479-4. [PubMed] [Cross Ref]
42. Taft WC, Yang K, Dixon CE, Hayes RL. Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. J Neurotrauma. 1992;9:281–290. doi: 10.1089/neu.1992.9.281. [PubMed] [Cross Ref]
43. Franz G, Beer R, Intemann D, et al. Temporal and spatial profile of Bid cleavage after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2002;22:951–958. doi: 10.1097/00004647-200208000-00006. [PubMed] [Cross Ref]
44. von Reyn CR, Spaethling JM, Mesfin MN, et al. Calpain mediates proteolysis of the voltage-gated sodium channel α-subunit. J Neurosci. 2009;29:10350–10356. doi: 10.1523/JNEUROSCI.2339-09.2009. [PMC free article] [PubMed] [Cross Ref]
45. Saatman KE, Graham DI, McIntosh TK. The neuronal cytoskeleton is at risk after mild and moderate brain injury. J Neurotrauma. 1998;15:1047–1058. doi: 10.1089/neu.1998.15.1047. [PubMed] [Cross Ref]
46. Posmantur RM, Hayes RL, Dixon CE, Taft WC. Neurofilament 68 and Neurofilament 200 protein levels decrease after TBI. J Neurotrauma. 1994;11:533–545. doi: 10.1089/neu.1994.11.533. [PubMed] [Cross Ref]
47. Serbest G, Burkhardt MF, Siman R, Raghupathi R, Saatman KE. Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice. Neurochem Res. 2007;32:2006–2014. doi: 10.1007/s11064-007-9318-9. [PubMed] [Cross Ref]
48. Huh JW, Laurer HL, Raghupathi R, Helfaer MA, Saatman KE. Rapid loss and partial recovery of neurofilament immunostaining following focal brain injury in mice. Exp Neurol. 2002;175:198–208. doi: 10.1006/exnr.2002.7880. [PubMed] [Cross Ref]
49. Posmantur RM, Zhao X, Kampft A, Clifton GL, Hayes RL. Immunoblot analyses of the relative contributions of cysteine and aspartic proteases to neurofilament breakdown products following experimental brain injury in rats. Neurochem Res. 1998;23:1265–1276. doi: 10.1023/A:1020792132629. [PubMed] [Cross Ref]
50. Posmantur R, Kampft A, Siman R, Liu J, Zhao X, Clifton GL, Hayes RL. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience. 1997;77:875–888. doi: 10.1016/S0306-4522(96)00483-6. [PubMed] [Cross Ref]
51. Liu MC, Akle V, Zheng W, et al. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J Neurochem. 2006;98:700–712. doi: 10.1111/j.1471-4159.2006.03882.x. [PubMed] [Cross Ref]
52. Zhang Z, Ottens AK, Sadasivan S, et al. Calpain-mediated collapsin response mediator protein-1, -2, and-4 proteolysis after neurotoxic and traumatic brain injury. J Neurotrauma. 2007;24:460–472. doi: 10.1089/neu.2006.0078. [PubMed] [Cross Ref]
53. Liu MC, Akle V, Zheng W, et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J. 2006;394:715–725. doi: 10.1042/BJ20051392. [PubMed] [Cross Ref]
54. Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis. 2004;16:311–320. doi: 10.1016/j.nbd.2004.03.016. [PubMed] [Cross Ref]
55. Hicks R, Soares H, Smith D, McIntosh T. Temporal and spatial characteristics of neuronal injury following lateral fluid-percussion brain injury in the rat. Acta Neuropathol. 1996;91:236–246. doi: 10.1007/s004010050421. [PubMed] [Cross Ref]
56. Fineman I, Hovda DA, Smith M, Yoshino A, Becker DP. Concussive brain injury is associated with a prolonged accumulation of calcium: a 45Ca autoradiographic study. Brain Res. 1993;624:94–102. doi: 10.1016/0006-8993(93)90064-T. [PubMed] [Cross Ref]
57. Hall ED, Gibson TR, Pavel KM. Lack of a gender difference in post-traumatic neurodegeneration in the mouse controlled cortical impact injury model. J Neurotrauma. 2005;22:669–679. doi: 10.1089/neu.2005.22.669. [PubMed] [Cross Ref]
58. Farkas O, Lifshitz J, Povlishock JT. Mechanoporation induced by diffuse traumatic brain injury: an irreversible or reversible response to injury? J Neurosci. 2006;26:3130–3140. doi: 10.1523/JNEUROSCI.5119-05.2006. [PubMed] [Cross Ref]
59. Hicks RR, Smith DH, Lowenstein DH, Saint Marie R, McIntosh TK. Mild experimental brain injury in the rat induces cognitive deficits associated with regional neuronal loss in the hippocampus. J Neurotrauma. 1993;10:405–414. doi: 10.1089/neu.1993.10.405. [PubMed] [Cross Ref]
60. Beer R, Franz G, Srinivasan A, et al. Temporal profile and cell subtype distribution of activated caspase-3 following experimental traumatic brain injury. J Neurochem. 2000;75:1264–1273. doi: 10.1046/j.1471-4159.2000.0751264.x. [PubMed] [Cross Ref]
61. Clark RSB, Kochanek PM, Watkins SC, et al. Caspase-3 mediated neuronal death after traumatic brain injury in rats. J Neurochem. 2000;74:740–753. doi: 10.1046/j.1471-4159.2000.740740.x. [PubMed] [Cross Ref]
62. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci. 1997;17:7415–7424. [PubMed]
63. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 2004;14:215–222. doi: 10.1111/j.1750-3639.2004.tb00056.x. [PubMed] [Cross Ref]
64. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT, Workshop Scientific Team and Advisory Panel Members Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008;25:719–738. doi: 10.1089/neu.2008.0586. [PMC free article] [PubMed] [Cross Ref]
65. Pineda JA, Wang KK, Hayes RL. Biomarkers of proteolytic damage following traumatic brain injury. Brain Pathol. 2004;14:202–209. doi: 10.1111/j.1750-3639.2004.tb00054.x. [PubMed] [Cross Ref]
66. Ottens AK, Golden EC, Bustamante L, Hayes RL, Denslow ND, Wang KK. Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. J Neurochem. 2008;104:1404–1414. doi: 10.1111/j.1471-4159.2007.05086.x. [PMC free article] [PubMed] [Cross Ref]
67. Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid α II-spectrin and calpain-cleaved α II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem. 2001;78:1297–1306. doi: 10.1046/j.1471-4159.2001.00510.x. [PubMed] [Cross Ref]
68. Aikman J, O’Steen B, Silver X, et al. α-II-spectrin after controlled cortical impact in the immature rat brain. Dev Neurosci. 2006;28:457–465. doi: 10.1159/000094171. [PubMed] [Cross Ref]
69. Ringger NC, O’Steen BE, Brabham JG, et al. A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J Neurotrauma. 2004;21:1443–1456. doi: 10.1089/neu.2004.21.1443. [PubMed] [Cross Ref]
70. Farkas O, Polgár B, Szekeres-Barthó J, Dóczi T, Povlishock JT, Büki A. Spectrin breakdown products in the cerebrospinal fluid in severe head injury: preliminary observations. Acta Neurochir (Wien) 2005;147:855–861. doi: 10.1007/s00701-005-0559-6. [PubMed] [Cross Ref]
71. Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of all-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24:354–366. doi: 10.1089/neu.2006.003789. [PubMed] [Cross Ref]
72. Cardali S, Maugeri R. Detection of all-spectrin and breakdown products in humans after severe traumatic brain injury. J Neurosurg Sci. 2006;50:25–31. [PubMed]
73. Brophy GM, Pineda JA, Papa L, et al. αII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009;26:471–479. doi: 10.1089/neu.2008.0657. [PMC free article] [PubMed] [Cross Ref]
74. Cox CD, West EJ, Liu MC, Wang KK, Hayes RL, Lyeth BG. Dicyclomine, an Ml muscarinic antagonist, reduces biomarker levels, but not neuronal degeneration, in fluid percussion brain injury. J Neurotrauma. 2008;25:1355–1365. doi: 10.1089/neu.2008.0671. [PMC free article] [PubMed] [Cross Ref]
75. Haranishi Y, Kawata R, Fukuda S, et al. Moderate hypothermia, but not calpain inhibitor 2, attenuates the proteolysis of microtubule-associated protein 2 in the hippocampus following traumatic brain injury in rats. Eur J Anaesthesiol. 2005;22:140–147. doi: 10.1017/S0265021505000268. [PubMed] [Cross Ref]
76. Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A. 1996;93:3428–3433. doi: 10.1073/pnas.93.8.3428. [PubMed] [Cross Ref]
77. Saatman KE, Zhang C, Bartus RT, Mclntosh TK. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. J Cereb Blood Flow Metab. 2000;20:66–73. doi: 10.1097/00004647-200001000-00010. [PubMed] [Cross Ref]
78. Lubisch W, Beckenbach E, Bopp S, et al. Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J Med Chem. 2003;46:2404–2412. doi: 10.1021/jm0210717. [PubMed] [Cross Ref]
79. Markgraf CG, Velayo NL, Johnson MP, et al. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke. 1998;29:152–158. [PubMed]
80. Buki A, Farkas O, Doczi T, Povlishock JT. Reinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury. J Neurotrauma. 2003;20:261–268. doi: 10.1089/089771503321532842. [PubMed] [Cross Ref]
81. Ai J, Liu E, Wang J, Chen Y, Yu J, Baker AJ. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007;24:960–978. doi: 10.1089/neu.2006.0224. [PubMed] [Cross Ref]
82. Guttmann RP, Baker DL, Seifert KM, Cohen AS, Coulter DA, Lynch DR. Specific proteolysis of the NR2 subunit at multiple sites by calpain. J Neurochem. 2001;78:1083–1093. doi: 10.1046/j.1471-4159.2001.00493.x. [PubMed] [Cross Ref]
83. Saatman KE, Bareyre FM, Grady MS, Mclntosh TK. Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency. J Neuropathol Exp Neurol. 2001;60:183–194. [PubMed]
84. Liu L, Yenari MA. Therapeutic hypothermia: neuroprotective mechanisms. Front Biosci. 2007;12:816–825. doi: 10.2741/2104. [PubMed] [Cross Ref]
85. Büki A, Koizumi H, Povlishock JT. Moderate posttraumatic hypothermia decreases early calpain-mediated proteolysis and concomitant cytoskeletal compromise in traumatic axonal injury. Exp Neurol. 1999;159:319–328. doi: 10.1006/exnr.1999.7139. [PubMed] [Cross Ref]
86. Temkin NR, Anderson GD, Winn HR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29–38. doi: 10.1016/S1474-4422(06)70630-5. [PubMed] [Cross Ref]
87. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med. 2001;344:556–563. doi: 10.1056/NEJM200102223440803. [PubMed] [Cross Ref]
88. Pettus EH, Christman CW, Giebel ML, Povlishock JT. Traumatically induced altered membrane permeability: its relationship to traumatically induced reactive axonal change. J Neurotrauma. 1994;11:507–522. doi: 10.1089/neu.1994.11.507. [PubMed] [Cross Ref]
89. Deng-Bryant Y, Singh IN, Carrico KM, Hall ED. Neuroprotective effects of tempol, a catalytic scavenger of peroxynitrite-derived free radicals, in a mouse traumatic brain injury model. J Cereb Blood Flow Metab. 2008;28:1114–1126. doi: 10.1038/jcbfm.2008.10. [PubMed] [Cross Ref]
90. Okonkwo DO, Büki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport. 1999;10:353–358. doi: 10.1097/00001756-199902050-00026. [PubMed] [Cross Ref]
91. Büki A, Okonkwo DO, Povlishock JT. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. J Neurotrauma. 1999;16:511–521. doi: 10.1089/neu.1999.16.511. [PubMed] [Cross Ref]
92. Mbye LH, Singh IN, Carrico KM, Saatman KE, Hall ED. Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. J Cereb Blood Flow Metab. 2009;29:87–97. doi: 10.1038/jcbfm.2008.93. [PMC free article] [PubMed] [Cross Ref]
93. Kupina NC, Detloff MR, Dutta S, Hall ED. Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. J Cereb Blood Flow Metab. 2002;22:1212–1221. doi: 10.1097/00004647-200210000-00009. [PubMed] [Cross Ref]

Articles from Neurotherapeutics are provided here courtesy of Springer